HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options            My Account    Help    
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Real Time Insight
Equity Research
My Portfolio
Stock Screener
Premium Screens
ETFs
Mutual Funds
Options
RSS Feed
Profit from the Pros
Subscription Services
Product Guide
Zacks Premium
Method for Trading
Chart Patterns Trader
Home Run Investor
Insider Trader
Options Trader
Reitmeister Trader
Reitmeister Value
Tactical Trader
Top 10 Stocks
Turnaround Trader
Whisper Trader
Research Wizard
Zacks Ultimate



Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


MASI: MASIMO CORP - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

MASIMO CORP (NASD)
MASI 22.71 0.53 (2.39%) Vol.  413,312 16:00 ET

Zacks Rank: 3 - Hold


Day Low - High 22.08 - 22.85
52wk Low - High 17.62 - 35.15
Avg Volume 451,053
Industry MED INSTRUMENTS
Market Cap 1.33 B
Div - Yield 0.00 - 0.00
PE (forward) 18.51
PEG Ratio 1.1
Current Year Est. 1.2
EPS Last Year 1.07
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.05%
# 2Buy18.22%
# 3Hold9.31%
# 4Sell3.69%
# 5Strong Sell1.45%
S&P5008.92%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
Zacks #1 Rank Strong Buys Zacks Premium
up 3 - Hold
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
All Outperform Rated Stocks Zacks Premium
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 11/15/2011
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
MASIMO CORP MASI 3
SYNERON MED LTD ELOS 1
ABIOMED INC ABMD 1
HANSEN MEDICAL HNSN 1
Top Peer Analysis Zacks Premium
See all MED INSTRUMENTS Peers

BROKERAGE RECOMMENDATIONS
Current ABR 2.08
ABR (Last Week) 2.08
# of Recs in ABR 12
Average Target Price 24.83
Rank in Industry 40 out of 55
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate MASI?
Buy
Sell
Find out what the Zacks Community
thinks of MASI at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 NEW!   Fundamental Charts




 
ZACKS COMMENTARY FOR MASI
Zacks Blog: Zacks Sell List Highlights: Pegasystems, Rovi, Masimo and ShangPharma
Dec 15, 2011
Zacks Blog: Masimo Remains Neutral
Nov 25, 2011
Zacks Equity Research: Report for MASI
Nov 15, 2011
Zacks Blog: Masimo Misses, Trims Guidance
Oct 31, 2011
Zacks Blog: Masimo Patient SafetyNet in France
Sep 15, 2011
Zacks Blog: Masimo Know-How Adopted in Honolulu
Sep 07, 2011
Zacks Blog: Masimo Stays at Neutral
Aug 22, 2011
Zacks Blog: Masimo EPS Meets, Sales Trail
Aug 10, 2011
More Zacks Commentary
NEWS
Masimo Corporation (MASI) Corporate Event Announcement Notice
Jan 28, 2012
Masimo Corporation (MASI) Corporate Event Announcement Notice - Story Title - Comtex
Jan 28, 2012
Masimo to Report Fourth Quarter and Full Year 2011 Financial Results After Market Close on February 14, 2012
Jan 26, 2012
Masimo to Report Fourth Quarter and Full Year 2011 Financial Results After Market Close on February 14, 2012 - Story Title - Comtex
Jan 26, 2012
Masimo Corporation (MASI) Corporate Event Announcement Notice
Jan 25, 2012
Buyers Accumulate Shares of Masimo, Up 2.2%
Jan 25, 2012
Buyers Accumulate Shares of Masimo, Up 2.2% - Story Title - Comtex
Jan 25, 2012
Masimo Corporation (MASI) Corporate Event Announcement Notice - Story Title - Comtex
Jan 25, 2012
More News
EARNINGS ESTIMATES
  This Quarter
12/2011
Next Quarter
03/2012
This Year
12/2011
Next Year
12/2012
Average Estimate 0.23 0.29 1.05 1.20
Number of Estimates 11 9 12 12
Low Estimates 0.21 0.27 1.03 1.14
High Estimate 0.25 0.31 1.07 1.28
Year Ago EPS 0.26 0.29 1.04 1.05
EPS Growth -10.84% 0.77% 0.88% 14.22%

More Estimates

COMPANY DESCRIPTION
Masimo develops innovative monitoring technologies that significantly improve patient care -- helping solve unsolvable problems. The company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it substantially reduced false alarms and increased pulse oximetry's ability to detect life-threatening events. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. Masimo has introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo has the mission of Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.

Full Company Report
FINANCIALS
EPS TTM 1.07
Sales 405.41
Net Income 65.99
Price/Earnings 20.73
Price/Book 4.47
Price/Cash Flow 18.83
Price/Sales 3.08


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2012 Zacks Investment Research